Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Lucid starts Envoy Medical at buy; PT $2

Lucid Capital Markets initiated coverage of Envoy Medical (NASDAQ:COCH) with a “buy” rating and price target of $2.00. The stock closed at $0.66 on July 24. Screenshot Envoy designs, manufactures, and is working to...

July 27, 2026

Developments

Incisionless TULSA Procedure for prostate cancer demonstrated statistically significant superior penile length preservation compared to Robotic Radical Prostatectomy at 1 month

The title of Profound Medical’s (NASDAQ:PROF; TSX:PRN) press release today, “Robotic Radical Prostatectomy Comes Up ‘Short’ in CAPTAIN Trial,” playfully set the tone for its reporting of a sensitive subject: penile...

July 24, 2026

Developments

Ukraine MoH Accepts Valion Bio’s Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway

Valion Bio (NASDAQ: VBIO) has announced that the regulatory dossier for its lead candidate, Entolimod for acute radiation syndrome (ARS), has been accepted by Ukraine’s Ministry of Health (MoH) for formal review...

July 22, 2026

Developments

Sheba Medical Center to self-sponsor a trial evaluating Valion Bio’s Entolimod in reducing radiation-induced neutropenia and protecting healthy tissue during cancer radiation therapy

Valion Bio (NASDAQ: VBIO) has announced a major clinical development milestone with the finalization of a clinical trial protocol at Sheba Medical Center, one of the world’s leading hospitals, to evaluate...

July 20, 2026

Developments

Casp-Aid appoints Mika Guerard as VP, Head of Drug Development

Closely held Casp-Aid has appointed Mika (Kimiaka C.) Guerard, PhD, MBA, as VP, Head of Drug Development as it makes final preparations to launch a Phase IIb clinical trial evaluating its lead small molecule, CIM765, in...

July 20, 2026

Developments

LIR and OH sign agreement to advance roadmap for transdermal obesity pipeline

LIR Life Sciences (CSE: SKNY; OTCPK: BBCMF) has announced that it has entered into a services agreement with closely held Oxygen Handel GmbH (OH), a specialized preclinical and regulatory development organization, to...

July 17, 2026

Developments

Dimerix acquires Phase 2-ready asset for acute kidney injury

Dimerix (ASX: DXB) has announced that it has acquired DMX-652 for all indications from closely held Mission Therapeutics, expanding its pipeline in rare kidney disease. DMX-652 is a novel first and best-in-class...

July 17, 2026

Developments

Neurology publishes Mobia’s two-year VNS-REHAB data demonstrating sustained stroke recovery

Mobia Medical (NASDAQ: MOBI) has announced the publication of two-year follow-up data from the VNS-REHAB study in Neurology, the peer-reviewed journal of the American Academy of Neurology, demonstrating that...

July 15, 2026

Developments

Fractyl reports positive one-year REMAIN-1 weight maintenance data

Fractyl Health (NASDAQ: GUTS) has announced positive one-year results from its REMAIN-1 Midpoint Cohort reinforcing the potential of the Revita DMR System to be the first durable procedural therapy for post-GLP-1 weight...

July 15, 2026

Developments

Profound Medical’s Autonomous Robotics and Incisionless Surgery to Have Strong Presence at SRS2026

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) announced that its MRI-guided, AI-powered, Robotically-Driven and Incisionless TULSA Procedure will be highlighted in several presentations by leading physicians at the...

July 15, 2026

Developments

Myricx to be acquired by Novartis for $1.5B

Closely held Myricx Bio has announced that it has reached an agreement to be acquired by Novartis (NYSE: NVS) for up to $1.5 billion including $1.1 billion cash upfront plus potential milestone payments. The acquisition...

July 14, 2026

Developments

USPTO grants Immutep new patent for eftilagimod alfa combined with PD-1 pathway inhibitors

Immutep (ASX: IMM; NASDAQ: IMMP) has announced that the United States Patent and Trademark Office (USPTO) granted a new patent for eftilagimod alfa in combination with a PD-1 pathway inhibitor for the treatment of...

July 14, 2026

Developments

Envoy reports improvement in speech perception in trial of cochlear implant

Envoy Medical (NASDAQ: COCH) has announced positive 12-month data from the first ten participants in Stage 1 of its pivotal clinical trial evaluating the investigational fully implanted Acclaim cochlear implant...

July 14, 2026

Developments

Valion advances integrated biodefense, immunology platform

Valion Bio (NASDAQ: VBIO) has provided an update for its Entolimod program—including continued engagement with U.S. government agencies and allied nations on Acute Radiation Syndrome (ARS) preparedness, a demonstrated...

July 14, 2026

Developments

VERAXA, Ardigen launch drug discovery collaboration

VERAXA Biotech (NASDAQ: VRXA) has announced a collaboration with closely held AI partner Ardigen to support VERAXA’s growing BiTAC pipeline of T-cell engagers and antibody-drug conjugates. According to VERAXA, the...

July 13, 2026

Developments

Virax signs immune profiling product supply deal with Fosun

Virax Biolabs (NASDAQ: VRAX) has announced the signing of an exclusive commercial supply agreement with Fosun Diagnostics, a subsidiary of Fosun Pharma (600196.SS; 02196.HK), for its research-use-only ImmuneSelect...

July 13, 2026

Developments

FDA grants RPD to Thiogenesis’ TTI-0102 for Leigh syndrome

Thiogenesis Therapeutics (TSXV: TTI; OTCQX: TTIPF) has announced that the FDA has granted Rare Pediatric Disease (RPD) designation to its lead candidate, TTI-0102, for the treatment of Leigh syndrome. Upon approval of a...

July 13, 2026

Developments

MIRA reports positive results supporting MIRA-55 as non-opioid oral pain therapy

MIRA Pharmaceuticals (NASDAQ: MIRA) has announced positive results from preclinical studies evaluating optimized oral formulations of MIRA-55, the company’s oral drug candidate being developed as a non-opioid...

July 10, 2026

Developments

Analysis shows 22% cut in NICU admissions in first-time pregnancies with Sera’s PreTRM

Sera Prognostics (NASDAQ: SERA) has announced publication of a new subgroup analysis from the PRIME trial demonstrating that its PreTRM Test-guided care in first-time pregnancies significantly improved neonatal...

July 10, 2026

Developments

Rani and PegBio join forces to expand obesity pipeline

Rani Therapeutics Holdings (NASDAQ: RANI) has announced a research and development collaboration with PegBio (SEHK: 2565) to explore the delivery of multiple novel candidates from PegBio’s obesity and metabolic...

July 10, 2026

Developments

Evogene and BCDD collaborate in drug discovery initiative

Evogene (NASDAQ: EVGN; TASE: EVGN) and Tel Aviv University’s Blavatnik Center for Drug Discovery (BCDD) have announced a collaboration that aims to expedite the development of small-molecule drug discovery originating...

July 9, 2026

Developments

CervoMed completes enrollment for study of neflamapimod in nfvPPA

CervoMed (NASDAQ: CRVO) has announced that it has completed enrollment in the Phase 2a study to evaluate the safety, pharmacokinetics, and clinical effects of neflamapimod in patients with nonfluent/agrammatic variant...

July 9, 2026

Subscribe